Eczema-Adjacent & Dry Skin Relief: Occlusive, Humectant & Emollient Layering Strategy

Overview #

pH is not just a formulation parameter in barrier-repair work — it is the primary determinant of whether your moisturizer actually repairs the skin or quietly disrupts it further. Eczema-adjacent and dry skin formulations sit at the intersection of three ingredient classes — occlusives, humectants, and emollients — that each behave differently under stress, interact with each other in ways most briefs don’t anticipate, and degrade through completely different mechanisms. We’ve run enough of these projects to know that the failure mode is almost never the active ingredient. It’s the layering strategy. Getting the stability and compatibility architecture right before you lock a formula is the difference between a product that performs at month 18 and one that separates, oxidizes, or loses efficacy by month 6.

Degradation Conditions and Numeric Thresholds #

The three ingredient classes in this system don’t share the same enemies. Occlusives — petrolatum, beeswax, C10-30 alkyl acrylate crosspolymer-based systems, dimethicone — are relatively inert, but they’re not immune. Petrolatum-heavy formulas stored above 45°C will phase-separate in packaging with poor thermal insulation. We’ve seen this in jar formats with dark pigmentation absorbing heat during transit. The wax matrix softens, the emulsion inverts, and by the time the product reaches the consumer it looks like it’s been melted and re-solidified. It has.

Humectants are a different story. Glycerin at concentrations above 20% in a water-continuous system will pull moisture from the formula itself under low-humidity storage conditions (below 30% RH), creating a paradox where the humectant destabilizes the emulsion it’s supposed to support. Hyaluronic acid — particularly high-molecular-weight fractions above 1,500 kDa — is sensitive to both pH and temperature. Below pH 4.0 or above pH 8.0, the polymer backbone begins to hydrolyze. We target pH 5.5–6.5 for HA-containing systems and hold that range tightly. Sodium PCA and betaine are more forgiving, but they’re also less effective at the concentrations brands typically want to use.

Emollients introduce the oxidation risk. Squalane is stable. Plant-derived oils — rosehip, sea buckthorn, evening primrose — are not. Linoleic acid content above 60% in a carrier oil means you’re working with a peroxidation clock. Without antioxidant protection (tocopherol at 0.1–0.5%, or a mixed tocopherol/rosemary extract system), these oils will hit rancidity thresholds within 6–9 months at 25°C in standard packaging. We require a minimum 0.2% tocopherol in any formula containing high-linoleic oils. That’s not negotiable on our end.

Temperature cycling is the stress condition most brands underestimate. A single freeze-thaw cycle at –5°C / +25°C can irreversibly break a poorly structured emulsion. We run 3 cycles minimum during stability screening. Most eczema-adjacent formulas use ceramide-rich emollient systems that are particularly vulnerable here because ceramides crystallize at low temperatures and don’t always re-disperse cleanly on warming.

Incompatible Combinations — Where Most Briefs Go Wrong #

The brief that comes in most often: “We want glycerin, hyaluronic acid, ceramides, niacinamide, and a peptide complex — all in one moisturizer.” Honestly, that’s not inherently impossible, but it requires sequencing decisions that most brands haven’t thought through.

Niacinamide and ascorbic acid in the same formula is the classic incompatibility. At temperatures above 40°C, they form nicotinic acid and dehydroascorbic acid through a condensation reaction. The result is a yellow discoloration and a formula that smells faintly of something it shouldn’t. We’ve seen this happen in stability chambers at week 4. The fix is either to separate them into a two-product system or to keep the ascorbic acid concentration below 0.5% — at which point you’re not really getting the brightening benefit anyway.

Cationic ingredients and anionic emulsifiers are another combination we push back on. If a brand wants a conditioning agent like behentrimonium chloride in a formula that uses sodium stearoyl glutamate as the primary emulsifier, the two will complex and precipitate. We’ve had one pilot batch fail exactly this way — the formula looked fine at 500g lab scale, but at 80kg production the mixing shear was different enough that the complex formed visible white aggregates by day 3. We now require compatibility screening for any cationic/anionic pairing before we scale.

Urea above 5% in combination with low-pH systems (below pH 5.0) will hydrolyze to ammonia over time. The pH drift is measurable — we’ve seen formulas shift 0.8 pH units upward over 12 weeks at 40°C when urea is combined with a citric acid buffer system without adequate buffering capacity. For eczema-adjacent formulas where urea is a key keratolytic, we buffer at pH 5.5–6.0 and use a phosphate-citrate system with enough capacity to hold that range.

The interaction between high-concentration glycerin and certain preservative systems is something we’re still not fully convinced the industry has characterized well enough. Our internal data suggests that glycerin above 15% can reduce the effective concentration of phenoxyethanol in the aqueous phase through partitioning effects. We compensate by increasing phenoxyethanol to 0.8–1.0% and adding ethylhexylglycerin as a booster. But the supplier data and our challenge test results don’t always agree on the margin.

Stability Parameters — What We Actually Test #

The table below reflects our standard stability protocol for barrier-repair moisturizers. These aren’t aspirational targets — they’re the pass/fail thresholds we apply before any formula moves to pilot production.

One thing this table doesn’t capture: the ceramide crystallization issue we mentioned earlier. We track that visually and by texture panel, not by instrument. It’s a judgment call, and we’ve had internal disagreements about what constitutes a fail. We haven’t fully solved this one. Our current approach works but it’s not elegant.

For formulas containing encapsulated actives, we add a capsule integrity test at week 4 and week 12 — encapsulation efficiency should remain above 85% at 40°C/75% RH. Below that, you’re releasing active prematurely and the in-use performance won’t match your claims.

Regulatory compliance for stability testing follows ICH Stability Guidelines for the accelerated and long-term conditions, adapted for cosmetic timelines. For EU market products, we align with EU Cosmetics Regulation 1223/2009 requirements on product stability and safety assessment documentation.

Clinical Evidence — What the Data Actually Shows #

The most relevant clinical reference we use internally for barrier-repair moisturizer benchmarking is a double-blind, randomized controlled trial (n=44, 8 weeks) comparing a ceramide-dominant emollient system (ceramide NP/AP/EOP at 3% total, with glycerin 8% and petrolatum 5%) against a glycerin-only control in subjects with mild-to-moderate atopic dermatitis. The ceramide-dominant arm showed a 38% reduction in TEWL at week 8 versus 17% in the control arm. Itch score (VAS) improved by 41% versus 22%. What the study doesn’t tell you — and what we’ve learned from our own batches — is that the ceramide system requires a specific emulsification approach to deliver those results. Ceramides are notoriously difficult to solubilize. If you’re not using a lamellar liquid crystal emulsification system or a ceramide-compatible co-emulsifier like phytosphingosine, you’re not getting the same skin deposition profile, and your clinical performance will be lower than the published data suggests.

We’re still not convinced the evidence base for synthetic ceramide blends versus plant-derived phytoceramides is strong enough to make a definitive recommendation. The mechanism is plausible. The in vitro data is consistent. But the head-to-head clinical data in eczema-adjacent populations is thin.

For brands targeting the EU market, the SCCS Scientific Opinion framework is the reference point for safety substantiation of any novel emollient or occlusive ingredient. For US market products, FDA Cosmetics Guidelines govern the OTC boundary — and some occlusive claims (particularly “skin protectant” language) trigger OTC drug classification, which changes your entire regulatory pathway.

Packaging — The Variable Most Brands Lock Too Early #

Packaging decisions for barrier-repair formulas should happen after stability screening, not before. We push back on this almost every project. Brands want to lock packaging at brief stage for cost and timeline reasons. We understand that. But we’ve rejected the first packaging vendor on two separate projects because the container material was incompatible with the formula’s emollient phase.

Petrolatum-heavy formulas will leach plasticizers from certain PP and PE grades over time. We require extractables and leachables testing for any formula with petrolatum above 10% or total hydrocarbon content above 15%. This is not optional for EU market products under EU Cosmetics Regulation 1223/2009.

Airless pump packaging is the right call for formulas containing high-linoleic oils or any ingredient sensitive to oxidative degradation. It adds $0.40–$0.80 per unit at MOQ 1,000 — most indie brands can’t absorb that at launch scale. The compromise we usually land on is a tube format with an aluminum barrier layer, which costs roughly $0.15–$0.25 more than standard PE tube and gives you meaningful oxygen protection without the airless pump price point.

Jar packaging for eczema-adjacent formulas is something we almost always push back on. Repeated finger-dipping introduces contamination, and the preservative system has to work harder to compensate. If a brand insists on jar for aesthetic reasons, we increase the preservative concentration and add a spatula recommendation in the packaging copy. It’s not a perfect solution.

For brands developing barrier-repair and sensitive skin product lines, the packaging decision is part of the stability story — not a downstream commercial decision.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask when a barrier-repair brief comes in, because the answers determine almost everything about the formulation architecture.

If you’re targeting EU eczema-adjacent claims, you need to be careful about the word “eczema” itself — it implies a therapeutic effect in most EU markets and can trigger medical device or drug classification. We typically help brands reframe to “dry, sensitive, eczema-prone skin” language, which stays within cosmetic territory.

If you’re targeting the US market with any “skin protectant” language, you’re in OTC drug territory and the active ingredient list is constrained by the FDA monograph. Colloidal oatmeal at 0.5–2.0% is the most commonly used OTC-compliant active in this space. Petrolatum at 30–100% is the other. Everything else is cosmetic.

For the formula itself: we typically start with a ceramide-glycerin-petrolatum backbone, adjust the emollient phase based on skin feel targets, and then layer in the humectant system. Fragrance-free is standard for this category — we’ve had too many projects where a fragrance addition at 0.3% triggered a stability issue in the preservative system. The NMPA registration pathway for China market products adds another layer — NMPA Cosmetic Regulation requires specific safety assessment documentation for any new ingredient, and some emollient actives that are routine in EU/US formulations require pre-registration in China.

MOQ for this category typically starts at 500kg per SKU on our production line. Pilot batches run at 50kg.

Frequently Asked Questions #

Q: We want to use rosehip oil as a hero ingredient — can we keep it stable in a moisturizer?

Yes, but you need antioxidant protection from day one. We use tocopherol at 0.3% minimum plus a chelating agent (EDTA or phytic acid) to suppress metal-catalyzed oxidation. Even then, expect a shelf life of 18 months maximum in tube packaging — 24 months is achievable only with aluminum barrier laminate.

Q: Our brief has glycerin at 25% — is that too high?

For a leave-on moisturizer, yes, in most cases. Above 20%, glycerin can feel tacky and may actually draw moisture out of the skin in low-humidity environments. We typically cap it at 15% and supplement with sodium PCA or betaine for additional humectancy without the texture penalty.

Q: Can we combine niacinamide and vitamin C in this formula?

Short answer: not in the same phase at meaningful concentrations. Above 40°C storage, the two react to form nicotinic acid — you’ll see yellowing by week 4 in stability. If both are required, we separate them into a two-step system or keep ascorbic acid below 0.5%, which limits the brightening benefit significantly.

Q: What preservative system works best for eczema-adjacent formulas?

We default to phenoxyethanol 0.8% + ethylhexylglycerin 0.3% for most projects. It passes USP 51 Category 2 at that level and has a reasonable EU consumer acceptance profile. For brands targeting a “clean” positioning, we’ve had success with a glyceryl caprylate + p-anisic acid system, but it requires pH below 6.0 to be effective — which constrains your formulation flexibility.

Q: How long does stability testing take before we can launch?

Minimum 3 months accelerated (40°C/75% RH) before we recommend a launch decision, with real-time testing running in parallel. For EU market products, the safety assessment requires at least 6 months of data. We’ve had brands try to launch on 6-week accelerated data — we push back on that every time. The failure rate on 6-week-only data in this category is too high to justify the risk.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.